IPP Bureau
Briefs: Ipca Laboratories, Lupin and Zydus
By IPP Bureau - June 05, 2023
The company has extended its full co-operation and support to the officials of the Income Tax Department
OMRON Healthcare to launch operations in March 2025 at Origins by Mahindra in Chennai
By IPP Bureau - June 05, 2023
The OMRON Healthcare factory will be built over 6.02 acres and will be manufacturing blood pressure monitors and supplying them mainly to the domestic market.
Evonik launches updated Biolys product for animal feeds
By IPP Bureau - June 05, 2023
The new Biolys provides higher concentration of L-lysine
DIC invests in US-based biotech startup
By IPP Bureau - June 05, 2023
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
International cooperation must to advance vaccine development for emerging pathogens: Health Minister Mandaviya
By IPP Bureau - June 04, 2023
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Celanese showcases advanced medical materials solutions at Medtec China 2023
By IPP Bureau - June 04, 2023
elanese now offers Zytel Resin, Hytrel TPC, Crastin PBT and Micromax Electronic Inks and Paste following its 2022 acquisition of the majority of the Mobility & Materials (M&M) business from DuPont
Sun Pharma and Philogen enter into an agreement for commercializing NIDLEGY
By IPP Bureau - June 03, 2023
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST
By IPP Bureau - June 03, 2023
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Sure Med Compliance partners with Galt Phranchise Systems to support better outcomes in pain patients
By IPP Bureau - June 03, 2023
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Novartis receives European approval for Cosentyx
By IPP Bureau - June 03, 2023
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
3M to invest nearly $150 million on expanding biopharma filtration capabilities
By IPP Bureau - June 03, 2023
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
AstraZeneca receives CDSCO approval for Tremelimumab combination in India
By IPP Bureau - June 02, 2023
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Evonik launches next-generation peptide for biopharma applications
By IPP Bureau - June 02, 2023
One thousand times more soluble than L-cystine at neutral pH
Philips and Masimo introduce advanced monitoring capabilities to Philips high acuity patient monitors
By IPP Bureau - June 02, 2023
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
By IPP Bureau - June 02, 2023
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
